Tissue Expression of Prohibition-I and It’s Relationship With Prognostic Factors in Breast Cancer

Hossein Javid1,2, Isaac Hashemy3, Soudabeh Shahidsales4, Nema Mohammadian Roshan5, Tayebeh Kianoosh1, Farnaz Zahedi Avval1,6*

1. Dept. of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2. Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3. Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
4. Dept. of Oncology, Omid Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5. Dept. of Pathology, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
6. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Breast Neoplasm; Prognosis; Immunohistochemistry

Background & objective: Globally, breast cancer is the most common malignancy among females. Prohibition (PHB)-I, a homologous protein, was initially introduced as a suppressor gene for amplification process. Further, the protein has a key role in the cell cycle and is capable of inhibiting DNA transcription in many cell types. Therefore, its possible role in different types of human malignancies is of interest. The current study aimed at examining the relationship between the tissue distribution of PHB-I and prognostic factors of breast cancer.

Methods: Paraffin-embedded tissue specimens of 33 patients diagnosed with breast cancer at Omid teaching Hospital, Mashhad, Iran were studied and a commercial monoclonal antibody was used to perform immunohistochemistry (IHC). The relationship between PHB-I tissue expression with age, disease stage, tumor grade and size, as well as hormone receptor status including estrogen (ER) and progesterone (PR) receptors, and Her-2 receptor were evaluated.

Results: The Immunohistochemical analysis showed a relative increase in PHB-I tissue expression along with higher tumor grade (P=0.057). In addition, higher expression of ER and PR were observed (P=0.027 and 0.009, respectively). The age of patients and other prognostic factors including Her-2 receptor status and disease stage did not statistically correlate with PHB-I expression.

Conclusion: An increased expression of PHB-I was observed in the breast cancer tumors of the current study patients compared with the anatomically healthy margin. Its coloration with some prognostic factors such as disease grade and expression of ER and PR might indicate the PHB-I potential application for diagnostic and patient management purposes.

ABSTRACT

Introduction

Breast cancer is the most common cancer among females. According to the World Health Organization (WHO) statistics, one out of 8-10 females is affected by breast cancer (1). Likewise in Iran, one out of 10-15 females is probably affected by breast cancer; however, the age of incidence of this cancer in Iranian populations is almost one decade earlier than that of the developed countries. It is noteworthy that breast cancer is the second cause of death resulting from cancer in Iran (2). Prognostic evaluations are essential in order to set disease management. Biomarkers are different proteins released from the cancer tissue (3). By examining these factors in serum or tissue samples, a model for prognosis assessment in many malignancies including breast cancer can be provid-
ed. The factors including biomarkers in the prognosis of the patients are continuously updated and revised.

Prohibition (PHB)-I is a homologous protein introduced for the first time as the suppressor gene of amplification during highly conserved evolution (4-6). Further studies revealed that this gene is located on the long arm of Chromosome 17. This area is genetically attached to the site predisposing the early onset of breast cancer (7). Moreover, it is observed that PHB-I has a major role in the cell cycle and can inhibit DNA transcription in different cell types (8-10).

It is observed that PHB-I in breast cancer cells binds to the p53 protein and increases p53 transcriptional activity (11). Therefore, PHB-I has a pivotal role in the function of “check point control” of p53 protein during the cell cycle. Additionally, studies demonstrate that PHB-I interacts with Rb protein, which inhibits the growth via binding and inhibiting E2F (12, 13). In some studies, a relationship between basal like and luminal type B tumors and PHB-I expression is reported (14). These findings indicate that PHB-I might have a tumor suppressor activity through regulation of the translation. Moreover, there are numerous studies indicating the definitive anti-tumorigenic role of PHB-I in some other cancers such as prostate cancer (15), gastric cancer (16), and hepatocellular malignancies (17).

In addition, PHB-I may act as an anchor in the cell membrane for C-Raf. Ras protein controls the cell signaling and collaborates with Raf protein kinase and finally activates MAPK (mitogen-activated protein kinase); thereby, biological order of growth is transferred and the cell growth is performed. In the absence of PHB-I, C-Raf activity stops; therefore, PHB-I may also play a key role in the progression of malignant transformation (18).

Some studies reported the increased expression of PHB-I gene in breast cancer (19), prostate cancer (20), and bladder cancer, and its significant relationship with prognostic factors such as disease stage and disease grade. On the other hand, some studies on gastric adenocarcinoma (16) and human glioma cell carcinoma (21) reported a significant reduction in expression of PHB gene. The increase or decrease of PHB-I expression is probably related to its subcellular status, which there are limited studies in this field (22). According to these controversial results, the role of PHB-I as a tumorigenic or tumor suppressor is still unclear; therefore, the current study aimed at investigating the distribution of PHB-I both in tumoral tissue and anatomically normal margin in Iranian patients with breast cancer.

**Method and Material**

The current cross sectional study was conducted on formalin fixed paraffin embedded (FFPE) tissue samples from 33 patients with breast cancer. The samples were obtained from the Department of Pathology, Omid teaching Hospital, Mashhad, Iran.

Patients’ data including age, hormone receptor status (ER, PR, and Her2 receptors), involved lymph nodes and metastasis condition, tumor grade (based on the pathologist’s report), and disease stage (according to American Joint Committee on Cancer Protocol) (23) were extracted from patients’ clinical files and recorded.

Immunohistochemistry (IHC) on FFPE samples was conducted based on LSAB (the labeled streptavidin–biotin) technique (24). Briefly, 4-micrometer tissue sections were prepared from the paraffin blocks. To ensure the fixation quality, hematoxylin and eosin (H & E) staining was performed. Next, special staining for PHB-I was conducted using the primary specific antibody. Thereafter, tissue pieces were floated on the slides coated with poly-alanine and immunohistochemical study of PHB-I was performed in the membrane of tumor cells using mouse PHB-I polyclonal antibody from Antibody Online Company (Cat. No. Orb80752), according to the manufacturer’s guidelines. For deparaffinization, the slides were dipped in xylene (for six minutes, twice), followed by immersion into 100%, 95%, 85% and 75% alcohol, respectively for two to three minutes. The slides were then treated with hydrogen peroxide in order to block the endogenous peroxidase activity. Afterwards, the tissue pieces were incubated with antimouse-PHB-I polyclonal antibody (Enzo life sciences, USA, dilu-
tion of 1:400, overnight at 4°C) and after the washing steps, the streptavidin-peroxidase-conjugated secondary antibody was added. Finally, the stained slides were washed with DAB (diaminobenzidine) in order to stop the color reaction.

Finally, slides were examined under a microscope with 40X and 100X magnifications. Gastric tumor tissue and anatomically normal marginal tissue samples, confirmed by an expert pathologist, served as positive and negative controls, respectively. The intensity of staining and abundance of positive cells were scored semi-quantitatively as provided in Tables 1 and 2, respectively. The intensity of observed stained cells scored 1 to 3 (weak to strong), and frequency of positive stained cells was determined as 0-25, 26-50, 51-75, and 76-100 (score 1 to 4) by an expert pathologist. The final score of PHB-I tissue expression was calculated by multiplying the recorded abundance and intensity scores. Data analysis was performed based on the calculated overall scores.

**Data analysis**

Categorical variables such as age, stage of the disease, and different hormone receptors were analyzed with SPSS version 16.0. A P-value of <0.05 was considered statistically significant in all calculations.

**Results**

The mean age of the patients was 45±1.5 years. Figure 1 represents the IHC staining of control samples and tumor tissues at different stages, respectively. Average tissue distribution of PHB-I in the studied patients scored 3.97±3.50. PHB-I tissue distribution score ranged 0 to 12. The frequency of the status of prognostic receptors among the patients is shown in Table 3.

Also, tissue expression of PHB-I did not significantly correlate with the stage of cancer (P=0.499) (Table 5), similarly, it had no significant relationship with tumor size (P=0.394). Likewise, the incidence of metastasis and the number of involved lymph nodes were independent of PHB-I expression (P=0.491 and 0.258; respectively).

As shown in Table 4, the average PHB-I tissue distribution in ER-positive patients was higher than that of the ER-negative group (P=0.027). Also, PHB-I tissue distribution in the PR-positive group was significantly higher than those of the PR-negative patients (P=0.009). No statistically significant relationship was observed between tissue expression of PHB-I and Her2 receptors (P=0.911). Tissue expression of PHB-I in patients with grade 1 was rather lower than that of grade 2 (2.27±2.14 vs. 4.80±3.58) (P=0.057).

| Table 1. Examining the Intensity of Staining in Immunohistochemistry Studies of Breast Cancer Tissue With 100X Magnification |
| --- |
| **Score** | **Intensity of staining** |
| 1 | Weak (light brown) |
| 2 | Moderate (chestnut brown) |
| 3 | Strong (dark brown) |

| Table 2. Examining the Severity of Staining in Immunohistochemistry Studies of Breast Cancer Tissue With 100X Magnification |
| --- |
| **Score** | **Abundance of Positive Cells** |
| 1 | Staining ≤25% of cells |
| 2 | Staining 26%-50% of cells |
| 3 | Staining 51%-75% of cells |
| 4 | Staining of ≥76% of cells |
**Figure 1.** Average distribution of tissue expression of PHB-I at different stages of cancer by optical microscope with magnification X40

A. Positive control (gastric tumor tissue)
B. Negative control (margin of healthy tissue)
C. Breast tissue samples with +1 intensity staining
D. Breast tissue samples with +2 intensity staining
E. Breast tissue samples with +3 intensity staining

**Table 3.** Frequency of the Status of Intended Different Receptors Among the Studied Patients

| Type of Receptors | ER (N) % | PR (N) % | HER-2 (N) % |
|-------------------|---------|----------|-------------|
| Positive          | 66.7    | 60.6     | 51.5        |
| Negative          | 33.3    | 39.4     | 48.5        |
| Total             | 100     | 100      | 100         |

**Table 4.** PHB Expression Score in Positive/Negative Patients for ER, PR, and Her2

| Type of Receptors | Positive  | Negative  | P value*  |
|-------------------|-----------|-----------|-----------|
| ER                | 4.95±3.59 | 2.18±2.27 | 0.027     |
| PR                | 5.25±3.47 | 2.15±2.47 | 0.009     |
| HER2**            | 3.75±3.50 | 3.95±3.24 | 0.911     |

*Student t test
**Negative and 1+ for Her2 were grouped as positive and 2+ and 3+ were grouped as negative.
Discussion

The concentration of biomarkers provides helpful data for a physician to determine disease severity and prognosis. Until now, multiple prognostic factors and predictive factors such as CA125, CA19-9, and CA15-3 are identified for breast cancer, and the value of some of them is completely proved; however, still no consensus is reached regarding other proposed factors (25-27).

It is essential to determine the prognosis of patients with cancer in order to set proper management of disease and also predict the disease outcome. Today, overall risk evaluation can be performed through clinical risk scoring systems (28). The status of tumor markers at the time of diagnosis is one of the tools used to determine the prognosis of breast cancer and subsequently the effect of adjuvant treatments such as chemotherapy. Improved prognostic models with newly included factors may provide developed clinical management schedules and treatment protocols. One of such new biomarkers is PHB-I, which might be promising for diagnostic purposes.

It is noted that one of the best methods to measure PHB-I is immunohistochemistry in which the rate of tissue expression can be determined based on the intensity and percentage of staining of the tumor tissue samples (29). In one study, immunohistochemical evaluations of breast cancer showed an increase in PHB-I expression in breast cancer cells and revealed a significant relationship between the increased expression and the breast tumor grade. Also, a direct relationship was observed between the increased PHB-I expression and clinico-pathological features such as ER and PR receptors (19). However, still summative studies are needed to further explore such observed relationships.

Results of the current study showed that the level of PHB-I expression increases along with an increase in the disease grade and also other prognostic factors such as ER- and PR-positivity. There are few studies linking between PHB-I and ER/PR, Her2 and prognosis of the patients and the results are controversial (30-32). Some factors including statistical issues and the included patients’ characteristics such as grade at the time of diagnosis might cause such contradictory observations.

No statistically significant relationship was observed between PHB-I and Her2 and disease stage. However, larger sample sizes might reveal a significant relationship. Due to contradictory results of the studies still additional studies preferably in a multicenter model are needed to confirm the results.

Conclusion

The current study showed an increase in PHB-I expression in breast cancer specimens in a sample of Iranian patients. A statistically significant relationship between tissue distribution and some prognostic factors such as ER and PR was observed. With the observed correlations, PHB-I might be a promising factor in breast cancer.

This original article was presented at the 7th International Conference and Expo on Molecular and Cancer Biomarkers in Berlin.

Funding

The study was supported by a grant (No 930825) from the Research Council of Mashhad University of Medical Sciences.

Ethical approval

The current study was reviewed and approved by the Ethical Committee of the Research Council of Mashhad University of Medical Sciences (Ethical
All procedures in the current study were performed in accordance with the ethical standards of the institutional/national research committee and with the 1964 Helsinki declaration and its additional amendments.

Conflict of Interest
Authors declared no conflict of interest.

References
1. Stagl JM. Benefits of Physical Activity on Depression and Functional Quality of Life During Treatment for Breast Cancer: Psychosocial Mechanisms. 2011.

2. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. Breast J. 2007;13(4):383-91. https://doi.org/10.1111/j.1524-4741.2007.00446.x PMID:17593043

3. Lumachi F, Basso SM. Serum tumor markers in breast cancer. Progress in Tumor Marker Research New York, NY: Nova Biomedical Books; 2007. p.83-100.

4. McClung JK, Danner DB, Stewart DA, Smith JR, Schneider EL, Lumpkin CK, et al. Isolation of a cDNA that hybrid selects antiproliferative mRNA from rat liver. Biochem Biophys Res Commun. 1989;164(3):1316-22. https://doi.org/10.1016/0006-291X(89)91813-5 PMID:2480116

5. Mishra S, Murphy LC, Murphy LJ. The Prohibitins: emerging roles in diverse functions. J Cell Mol Med. 2006;10(2):353-63. https://doi.org/10.1111/j.1582-4934.2006.tb00404.x PMID:16796804 PMCID:PMC3933126

6. Nijtmans L, Sanz MA, Grivell L, Coates P. The mitochondrial PHB complex: roles in mitochondrial respiratory complex assembly, ageing and degenerative disease. Cell Mol Life Sci. 2002;59(1):143-55. https://doi.org/10.1007/s00018-002-8411-0 PMID:11852914

7. Sato T, Saito H, Swensen J, Olifant A, Wood C, Danner D, et al. The human prohibitin gene located on chromosome 17q21 is mutated in sporadic breast cancer. Cancer Res. 1992;52(6):1643-6. PMID:1540973

8. Berger KH, Yaffe MP. Prohibitin family members interact genetically with mitochondrial inheritance components in Saccharomyces cerevisiae. Mol Cell Biol. 1998;18(7):4043-52. https://doi.org/10.1128/MCB.18.7.4043 PMID:9632789 PMCID:PMC108989

9. Coates P, Jamieson D, Smart K, Prescott A, Hall P. The prohibitin family of mitochondrial proteins regulate replicative lifespan. Curr Biol. 1997;7(8):607-10. https://doi.org/10.1016/S0960-9822(06)00261-2 PMID:9259555

10. Coates P, Nenutil R, McGregor A, Picksley S, Crouch D, Hall P, et al. Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence. Exp Cell Res. 2001;265(2):262-73. https://doi.org/10.1006/excr.2001.5166 PMID:11302691

11. Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S. Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem. 2003;278(48):47853-61. https://doi.org/10.1074/jbc.M305171200 PMID:14500729

12. Wang S, Fusaro G, Padmanabhan J, Chellappan SP. Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene. 2002;21(55):8388-96. https://doi.org/10.1038/sj.onc.1205944 PMID:12466959

13. Wang S, Nath N, Adlam M, Chellappan S. Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene. 1999;18(23):3501-10. https://doi.org/10.1038/sj.onc.1202684 PMID:10376528

14. Mackay A, Tamber N, Fenwick K, Iravani M, Grigoriadis A, Dexter T, et al. A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat. 2009;118(3):481. https://doi.org/10.1007/s10549-008-0296-7 PMID:19169812
Tissue Expression of ... 

15. Dart DA, Spencer-Dene B, Gamble SC, Waxman J, Bevan CL. Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours. Endocr Relat Cancer. 2009;16(4):1157-69. https://doi.org/10.1677/ERC-09-0028 PMID:19635783 PMCID:PMC2782800

16. Liu T, Tang H, Lang Y, Liu M, Li X. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett. 2009;273(2):233-42. https://doi.org/10.1016/j.canlet.2008.08.003 PMID:18789835

17. Ko KS, Tomasi ML, Iglesias-Ara A, French BA, French SW, Ramani K, et al. Liver-specific deletion of prohibitin 1 results in spontaneous liver injury, fibrosis, and hepatocellular carcinoma in mice. Hepatology. 2010;52(6):2096-108. https://doi.org/10.1002/hep.23919 PMID:20890892 PMCID:PMC3005187

18. Rajalingam K, Wunder C, Brinkmann V, Churin Y, Hekman M, Sievers C, et al. Prohibitin is required for Ras-induced Raf–MEK–ERK activation and epithelial cell migration. Nat Cell Biol. 2005;7(8):837-43. https://doi.org/10.1038/ncb1283 PMID:16041367

19. Najm MZ, Zaidi S, Siddiqui WA, Husain SA. Immunohistochemical expression and mutation study of prohibitin gene in Indian female breast cancer cases. Med Oncol. 2013;30(3):614. https://doi.org/10.1007/s12032-013-0614-8

20. Ummanni R, Junker H, Zimmermann U, Venz S, Teller S, Giebel J, et al. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Cancer Lett. 2008;266(2):171-85. https://doi.org/10.1016/j.canlet.2008.02.047 PMID:18384941

21. Chumbalkar VC, Subhashini C, Dhople VM, Sundaram CS, Jagannadham MV, Kumar KN, et al. Differential protein expression in human gliomas and molecular insights. Proteomics. 2005;5(4):1167-77. https://doi.org/10.1002/pmic.200401202 PMID:15759318

22. Rastogi S, Joshi B, Fusaro G, Chellappan S. Camptothecin induces nuclear export of prohibitin preferentially in transformed cells through a CRM-1-dependent mechanism. J Biol Chem. 2006;281(5):2951-9. https://doi.org/10.1074/jbc.M508669200 PMID:16319068

23. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917-31. https://doi.org/10.1200/JCO.2006.06.5888 PMID:16651642

24. Key M. Immunohistochemistry Staining Methods, Education Guide. 4nd ed. Carpinteria, CA: Dako; 2006. p.47. dieypl.us/~bryan/irc/protocol-online/protocol.../08002_25may06_Ihc_guide_book.pdf

25. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251(3):499-505. https://doi.org/10.1097/SLA.0b013e3181e939f PMID:20134314

26. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-312. https://doi.org/10.1200/JCO.2007.14.2364 PMID:17954709

27. Kumar R. Breast cancer tumor markers. Journal of Solid Tumors. 2012;2(1):43. https://doi.org/10.5430/jst.v2n1p43

28. Groheux D, Giaccchetti S, Moretti J-L, Porcher R, Espié M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38(3):426-35. https://doi.org/10.1007/s00259-010-1640-9 PMID:21057787

29. Allred D, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155-68. PMID:9504686

30. Paula LM, Moraes LHFD, Canto ALD, Dos Santos L, Martin AA, Rogatto SR, et al. Analy-
sis of molecular markers as predictive factors of lymph node involvement in breast carcinoma. Oncol Lett. 2017;13(1):488-96. https://doi.org/10.3892/ol.2016.5438 PMID:28123587 PMCID:PMC5244838

31. Canevari RA, Marchi FA, Domingues MA, de Andrade VP, Caldeira JR, Verjovski-Almeida S, et al. Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma. Tumour Biol. 2016;37(10):13855-70. https://doi.org/10.1007/s13277-016-5133-8 PMID:27485113

32. Liu P, Xu Y, Zhang W, Li Y, Tang L, Chen W, et al. Prohibitin promotes androgen receptor activation in ER-positive breast cancer. Cell Cycle. 2017;16(8):776-84. https://doi.org/10.1080/15384101.2017.1295193 PMID:28272969 PMCID:PMC5405713

How to Cite This Article

Javid H, Hashemy I, Shahid sales S, Mohammadian Roshan N, Kianoosh T, Zahedi Avval F. Tissue Expression of Prohibition-I and Its Relationship With Prognostic Factors in Breast Cancer. Iranian Journal of Pathology, 2018; 13(2): 237-244.